Rhythm Wins FDA Nod for Hypothalamic Obesity Therapy

An update from Rhythm Pharmaceuticals ( (RYTM) ) is now available.

On March 19, 2026, Rhythm Pharmaceuticals reported that the U.S. Food and Drug Administration approved an expanded indication for its MC4R agonist IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity in adults and children aged four and older. Acquired hypothalamic obesity is a rare condition often following hypothalamic tumors or injury, and Rhythm estimates about 10,000 affected patients in the U.S., underscoring a concentrated but meaningful commercial niche.

The expanded label makes IMCIVREE the first and only FDA-approved therapy specifically for acquired hypothalamic obesity, potentially strengthening Rhythm’s leadership in rare obesity disorders and filling a critical treatment gap for patients facing relentless hunger and rapid, sustained weight gain. Approval was based on the global Phase 3 TRANSCEND trial in 142 patients, where setmelanotide achieved an 18.4% placebo-adjusted reduction in BMI and was generally well tolerated, and the company plans immediate U.S. availability supported by its Rhythm InTune patient services program.

The most recent analyst rating on (RYTM) stock is a Buy with a $149.00 price target. To see the full list of analyst forecasts on Rhythm Pharmaceuticals stock, see the RYTM Stock Forecast page.

Spark’s Take on RYTM Stock

According to Spark, TipRanks’ AI Analyst, RYTM is a Neutral.

The score is driven primarily by improving commercial traction and strong gross margins alongside a low-debt balance sheet, but it is held back by ongoing cash burn and losses. Technicals remain weak with the stock below key moving averages and negative momentum, while near-term outlook is mixed given higher 2026 spending guidance and mixed Phase 3 expansion data despite supportive AHO regulatory/clinical catalysts.

To see Spark’s full report on RYTM stock, click here.

More about Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. is a Boston-based commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, particularly severe obesity driven by dysfunction in the MC4R pathway. Its lead drug, IMCIVREE (setmelanotide), is approved in the U.S., European Union and U.K. for certain forms of syndromic and monogenic obesity, and the company is advancing additional MC4R agonists and programs in congenital hyperinsulinism.

Rhythm targets niche populations with high unmet medical need, such as patients with Bardet-Biedl syndrome and POMC, PCSK1 or LEPR deficiency, aiming to build a franchise in rare obesity disorders. By expanding indications for IMCIVREE and progressing its pipeline, the company is positioning itself as a specialized player in the rare endocrine and metabolic disease market.

Average Trading Volume: 715,185

Technical Sentiment Signal: Hold

Current Market Cap: $6.17B

For a thorough assessment of RYTM stock, go to TipRanks’ Stock Analysis page.